Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenolid vs Viread Switching in Chronic Hepatitis B
NCT05282407Phase 4Completed
- Sponsor
- Samjin Pharmaceutical Co., Ltd.
- Start
- Nov 2017
- Primary completion
- Apr 2019
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in hepatitis B (HBV) (2 arms), sponsored by Samjin Pharmaceutical Co., Ltd. Primary endpoint: Inhibiting rate of HBV virus at 48 weeks. Started Nov 2017; status: completed.
02
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT05282407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05282407.